186 related articles for article (PubMed ID: 22536082)
1. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease.
Ohashi N; Sakao Y; Yasuda H; Kato A; Fujigaki Y
Int J Nephrol Renovasc Dis; 2012; 5():53-60. PubMed ID: 22536082
[TBL] [Abstract][Full Text] [Related]
2. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N; Awaisu A
Int J Clin Pharm; 2014 Dec; 36(6):1115-25. PubMed ID: 25288147
[TBL] [Abstract][Full Text] [Related]
3. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
4. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease.
Curran MP; McCormack PL
Drugs; 2008; 68(8):1139-56. PubMed ID: 18484803
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
Locatelli F; Hannedouche T; Fishbane S; Morgan Z; Oguey D; White WB
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1701-1710. PubMed ID: 31420350
[TBL] [Abstract][Full Text] [Related]
6. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.
Schmid H
Expert Rev Hematol; 2016 Jan; 9(1):5-20. PubMed ID: 26573694
[TBL] [Abstract][Full Text] [Related]
7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta.
Wedekin M; Ehrich JH; Pape L
Pediatr Transplant; 2011 May; 15(3):329-33. PubMed ID: 21338458
[TBL] [Abstract][Full Text] [Related]
9. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
Thamer M; Zhang Y; Kshirsagar O; Cotter DJ; Kaufman JS
Am J Kidney Dis; 2014 Nov; 64(5):706-13. PubMed ID: 25011692
[TBL] [Abstract][Full Text] [Related]
11. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease.
Minutolo R; Garofalo C; Chiodini P; Aucella F; Del Vecchio L; Locatelli F; Scaglione F; De Nicola L
Nephrol Dial Transplant; 2021 Jan; 36(2):267-274. PubMed ID: 32829405
[TBL] [Abstract][Full Text] [Related]
12. Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease.
Al Raisi F; Al Salmi I; Kamble P; Al Shehri M; Shaheen FA
Saudi J Kidney Dis Transpl; 2016; 27(6):1182-1187. PubMed ID: 27900963
[TBL] [Abstract][Full Text] [Related]
13. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
14. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
Shingu Y; Nakata T; Sawai S; Tanaka H; Asai O; Tamagaki K; Nakatani K
BMC Nephrol; 2020 Jul; 21(1):275. PubMed ID: 32664894
[TBL] [Abstract][Full Text] [Related]
15. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
17. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?
Schmidt RJ
Expert Opin Pharmacother; 2009 Jun; 10(9):1509-14. PubMed ID: 19505218
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
19. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Hörl WH
Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
[TBL] [Abstract][Full Text] [Related]
20. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
